11 September 2017 - The EMA has published a draft agenda for this week's CHMP meeting.

The CHMP is due to issue initial opinions for the following technologies:

• Adalimumab
  
• Fluticasone furoate with vilanterol trifenatate and umeclidinium bromide
  
• Guselkumab
  
• Imatinib mesylate
  
• Miglustat
  
• Naloxone hydrochloride
  
• Ocrelizumab
  
• Trastuzumab
  
• Ritonavir
  
• Padeliporfin
  
• Fibrinogen (human) with thrombin (human)
  
• Niraparib tosylate monohydrate
  
• Buprenorphine with naloxone hydrochloride
  

Read CHMP agenda